Assessing the Efficacy of Secukinumab in Psoriasis Patients

Purpose

The purpose of the study is to see if secukinumab has an effect on fatty tissue beneath the skin and on skin inflammation in patients with psoriasis. This study will also look at blood tests, or “markers,” that could help identify risk for heart disease and metabolic diseases like diabetes or cardiometabolic disease. Secukinumab (Cosentyx®) is a prescription medicine that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis in adults.

Keywords: psoriasis, plaque psoriasis, inflammation, dermatology

Study Sites

Keck School of Medicine, Los Angeles 90033

 
  • Men & Women
Age icon
18+
 

We're sorry, but this trial is no longer enrolling volunteers.

What's involved?

Study length

  • 1 year

Number of visits

  • 16

Prescription

  • Secukinumab

Procedures

  • Skin biopsies (a sample of your skin)

Compensation

  • Compensation is available for completion of each regular study visit.

Medical cost coverage

  • All study-related visits, tests, and study drug will be provided at no cost to the participant.

Why participate?

Medical advances are impossible without volunteers.

Eligibility

Must have

  • Diagnosis of moderate-to-severe psoriasis
  • 18 years or older

Can't have

    There are no exclusion criteria

About This Study

If you are eligible for this study, you will be randomly assigned, like the flip of a coin, to a treatment with secukinumab OR a placebo injections (do not contain active medication) for the first 3 months. After 3 months, no matter which study drug you were first assigned to, you will begin receiving secukinumab until the end of the one-year study. Your total study participation will last about 12–13 months, which includes up to 16 study clinic visits where doctors and the study staff will conduct various tests to evaluate your health and progress. By taking part in this study, you will make an important contribution to moderate to severe plaque psoriasis treatment research.

Study Team

Klzgupjvszojzdlowlmy
Principal Investigator
April W. Armstrong, MD MPH

For questions about this study, contact:

Research study materials

We respect your privacy!

All the information you give us is stored in a secure, password protected database. All the information that you choose to share will be kept private and confidential. Read University of Southern California's Privacy Policy here.